We compared the survival outcomes of non-DIPG DMG patients whose tumor location was outside the pons/brainstem with TGFB2 mRNA expression levels greater than or equal to the upper quartile (TGFB2high) to the treatment outcomes of the remaining non-DIPG DMG patients (TGFB2low). The gene discussed is TGFB2; the disease is neoplasm.